Immunogenicity of an inactivated hepatitis A pediatric vaccine: Three-year post-booster follow-up

Vaccine

Volumn 23, Issue 44, 2005, Pages 5144-5148

  Dagan, Ron ^a,b   Greenberg, David ^a,b   Weber, Françoise ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c SANOFI PASTEUR   (France)

Author keywords

Antibody persistence; Children; Hepatitis A vaccine

Indexed keywords

ANTIBIOTIC AGENT; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FOLLOW UP; GEOMETRY; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NORMAL HUMAN; PEDIATRICS; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 25144438915     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.06.017     Document Type: Article

References (18)

1. J.M. Lieberman, and D.P. Greenberg Hepatitis A and B vaccines in children Adv Pediatr Infect Dis 11 1996 333 363
2. C.N. Shapiro, and S.C. Hadler Significance of hepatitis in children in day care Semin in Pediatr Infect Dis 1 1990 270 279
3. C. Goilav, J. Zuckerman, M. Lafrenz, E. Vidor, S. Lauwers, and C. Ratheau Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study J Med Virol 46 3 1995 287 292
4. U. Heinricy, Y.D. Stierhof, M. Pfisterer, and B. Flehmig Properties of a hepatitis A virus candidate vaccine strain J Gen Virol 68 Pt 9 1987 2487 2493
5. E. Vidor, B. Fritzell, and S. Plotkin Clinical development of anew inactivated hepatitis A vaccine Infect 24 1996 447 458
6. J. Zuckerman, F. Peyron, M. Wallon, F. Gay, H. Delolme, and P. Briantais Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines Advances Therapy 14 3 1997 116 124
7. S. Lolekha, S. Pratuangtham, W. Punpanich, P. Bowonkiratikachorn, K. Chimabutra, and F. Weber Immunogenicity and safety of two doses of a paediatric hepatitis a vaccine in thai children: comparison of three vaccination schedules J Trop Pediatr 49 2003 333 339
8. E.L. Lopez, M. Del Carmen Xifro, L.E. Torrado, M.F. De Rosa, R. Gomez, and R. Dumas Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children Pediatr Infect Dis J 20 2000 48 52
9. R. Dagan, D. Greenberg, P. Goldenbertg-Gehtman, E. Vidor, P. Briantais, and V. Pinsk Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine Vaccine 17 1999 1919 1925
10. G.G. Frosner, L.R. Overby, and B. Flehmig Serological investigation of patients and family contacts in an epidemic of hepatitis A J Med Virol 1 1977 163 173
11. W.J. Miller, W. Clark, W. Hurni, B. Kuter, T. Schofield, and D. Nalin Sensitive assays for hepatitis A antibodies J Med Virol 41 3 1993 201 204
12. E. Vidor, R. Dumas, V. Porteret, F. Bailleux, and K. Veitch Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data Eur J Clin Microbiol Infect Dis 23 4 2004 300 309
13. A.S. Craig, and W. Schaffner Prevention of hepatitis A with the hepatitis A vaccine N Engl J Med 350 5 2004 476 481
14. Dagan R, Leventhal A, Anis E, Slater P, Shouval D. National hepatitis a virus (HAV) immunization program aimed exclusively at toddlers in an endemic country resulting in >90% reduction in morbidity rate in all ages [Abstract # 825], 40th Annual Meeting of the Infectious Diseases Society of America, 24-27 October 2002, Chicago, IL.
15. C.N. Shapiro, and H.S. Margolis Worldwide epidemiology of hepatitis A virus infection J Hepatol 18 Suppl. 2 1993 S11 S14
16. Centers for Disease Control and Prevention, CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48 (no. RR-12).
17. A. Montano, M.C. Pirez, H. Dibarboure, and R. Debbag Cost/benefit analysis, universal hepatitis A vaccination in Uruguay Int J Infect Diseases 8 Suppl. 2004 S228
18. R.J. Jacobs, D.P. Greenberg, R.S. Koff, S. Saab, and A.S. Meyerhoff Regional variation in the cost effectiveness of childhood hepatitis A immunization Pediatr Infect Dis J 22 10 2003 904 914